Of note, although high PD-L1 expression on tumor cells was associated with response to anti-PD-1 therapies in various malignancies, patients with PD-L1-negative tumors by immunohistochemistry can still achieve clinical benefit with anti-PD-1 or anti-PD-L1 therapies [7, 8]. This evidence concerns the gene PDCD1 and neoplasm.